Literature DB >> 23934482

NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype.

Mizuki Yamamoto1, Yuu Taguchi, Taku Ito-Kureha, Kentaro Semba, Noritaka Yamaguchi, Jun-ichiro Inoue.   

Abstract

Patients with triple-negative breast cancer display the highest rates of early relapse of all patients with breast cancer. The basal-like subtype, a subgroup of triple-negative breast cancer, exhibits high levels of constitutively active NF-κB signalling. Here we show that NF-κB activation, induced by inflammatory cytokines or by epigenetically dysregulated NIK expression, cell-autonomously upregulates JAG1 expression in non-cancer stem cells. This upregulation stimulates NOTCH signalling in cancer stem cells in trans, leading to an expansion of cancer stem cell populations. Among breast cancers, the NF-κB-dependent induction of JAG1 and the NOTCH-dependent expansion of the cancer stem cell population occur only in the basal-like subtype. Collectively, our results indicate that NF-κB has a non-cell-autonomous role in regulating cancer stem cell populations by forming intratumoural microenvironments composed of JAG1-expressing non-cancer stem cells with a basal-like subtype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934482     DOI: 10.1038/ncomms3299

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  88 in total

Review 1.  NF-κB signaling in cancer stem cells: a promising therapeutic target?

Authors:  K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado
Journal:  Cell Oncol (Dordr)       Date:  2015-08-29       Impact factor: 6.730

Review 2.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

3.  Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells.

Authors:  Irida Kastrati; Loruhama Delgado-Rivera; Gergana Georgieva; Gregory R J Thatcher; Jonna Frasor
Journal:  J Vis Exp       Date:  2017-01-18       Impact factor: 1.355

4.  Jagged-Delta asymmetry in Notch signaling can give rise to a Sender/Receiver hybrid phenotype.

Authors:  Marcelo Boareto; Mohit Kumar Jolly; Mingyang Lu; José N Onuchic; Cecilia Clementi; Eshel Ben-Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

5.  Developmental Insights into Breast Cancer Intratumoral Heterogeneity.

Authors:  Mei Zhang; Jeffrey M Rosen
Journal:  Trends Cancer       Date:  2015-12-01

6.  Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.

Authors:  Naing Lin Shan; Joseph Wahler; Hong Jin Lee; Min Ji Bak; Soumyasri Das Gupta; Hubert Maehr; Nanjoo Suh
Journal:  J Steroid Biochem Mol Biol       Date:  2016-12-05       Impact factor: 4.292

Review 7.  Epithelial-to-mesenchymal transition in tumor progression.

Authors:  Elena Prieto-García; C Vanesa Díaz-García; Inmaculada García-Ruiz; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2017-05-30       Impact factor: 3.064

8.  DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer.

Authors:  Chunhua Han; Ran Zhao; Xingluo Liu; Amit Srivastava; Li Gong; Hsiaoyin Mao; Meihua Qu; Weiqiang Zhao; Jianhua Yu; Qi-En Wang
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

Review 9.  NF-κB, inflammation, immunity and cancer: coming of age.

Authors:  Koji Taniguchi; Michael Karin
Journal:  Nat Rev Immunol       Date:  2018-01-22       Impact factor: 53.106

Review 10.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.